Stephanie L. Baross

Stephanie L. Baross

Auto-generated profile, based on publicly available information

Stephanie L. Baross

Division of Cardiovascular Sciences, Faculty of Biology, Medicine and Health, The University of Manchester, Manchester, UK

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 June 2018 in Nature Communications
Verified
Journal Article
Open access
PDF file
MCMun-Kit Choy
Mun-Kit Choy
Biola M. JavierreBiola M. Javierre
Biola M. Javierre
SWSimon G. Williams
Simon G. Williams
SBStephanie L. Baross
Stephanie L. Baross
YLYingjuan Liu
Yingjuan Liu
BKBernard D. Keavney
Bernard D. Keavney
Long-range chromosomal interactions bring distal regulatory elements and promoters together to regulate gene expression in biological processes. By performing promoter capture Hi-C (PCHi-C) on human embryonic stem cell-derived cardiomyocytes (hESC-CMs), we show that such promoter interactions are a key mechanism by which enhancers contact their target genes after hESC-CM differentiation from hESCs. We also show that the promoter interactome of hESC-CMs is associated with expression quantitative trait loci (eQTLs) in cardiac left ventricular tissue; captures the dynamic process of genome reorganisation after hESC-CM differentiation; overlaps genome-wide association study (GWAS) regions associated with heart rate; and identifies new candidate genes in such regions. These findings indicate that regulatory elements in hESC-CMs identified by our approach control gene expression involved in ventricular conduction and rhythm of the heart. The study of promoter interactions in other hESC-derived cell types may be of utility in functional investigation of GWAS-associated regions.

26 November 2024 in European Journal of Human Genetics
Verified
Journal Article
Open access
PDF file
VHVerity Hartill
Verity Hartill
MKMitra Kabir
Mitra Kabir
SBSunayna Best
Sunayna Best
WQWasay Mohiuddin Shaikh Qureshi
Wasay Mohiuddin Shaikh Qureshi
SBStephanie L. Baross
Stephanie L. Baross
CJColin A. Johnson
Colin A. Johnson
Congenital heart disease (CHD) describes a structural cardiac defect present from birth. A cohort of participants recruited to the 100,000 Genomes Project (100 kGP) with syndromic CHD (286 probands) and familial CHD (262 probands) were identified. “Tiering” following genome sequencing data analysis prioritised variants in gene panels linked to participant phenotype. To improve diagnostic rates in the CHD cohorts, we implemented an agnostic de novo Gene Discovery Pipeline (GDP). We assessed de novo variants (DNV) for unsolved CHD participants following filtering to select variants of interest in OMIM-morbid genes, as well as novel candidate genes. The 100kGP CHD cohorts had low rates of pathogenic diagnoses reported (combined CHD “solved” 5.11% (n = 28/548)). Our GDP provided diagnostic uplift of nearly one third (1.28% uplift; 5.11% vs. 6.39%), with a new or potential diagnosis for 9 additional participants with CHD. When a filtered DNV occurred within a non-morbid gene, our GDP prioritised biologically-plausible candidate CHD genes (n = 79). Candidate variants occurred in both genes linked to cardiac development (e.g. AKAP13 and BCAR1) and those currently without a known role (e.g. TFAP2C and SETDB1). Sanger sequencing of a cohort of patients with CHD did not identify a second de novo variant in the candidate dataset. However, literature review identified rare variants in HMCN1, previously reported as causative for pulmonary atresia, confirming the approach utility. As well as diagnostic uplift for unsolved participants of the 100 kGP, our GDP created a dataset of candidate CHD genes, which forms an important resource for further evaluation.

8 November 2024 in bioRxiv
Verified
Preprint
Open access
PDF file
MKMitra Kabir
Mitra Kabir
VHVerity Hartill
Verity Hartill
GFGist H. Farr
Gist H. Farr
WQWasay Mohiuddin Shaikh Qureshi
Wasay Mohiuddin Shaikh Qureshi
SBStephanie L. Baross
Stephanie L. Baross
KHKathryn Hentges
Kathryn Hentges
Congenital heart disease (CHD) is a major cause of infant mortality and presents life-long challenges to individuals living with these conditions. Genetic causes are known for only a minority of types of CHD. Discovering further genetic causes is limited by challenges in prioritising candidate CHD genes. We examined a wide range of features of mouse genes, including sequence characteristics, protein localisation and interaction data, developmental expression data and gene ontology annotations. Many features differ between cardiac development and non-cardiac genes, suggesting that these two gene types can be distinguished by their attributes. Therefore, we developed a supervised machine learning (ML) method to identify Mus musculus genes with a high probability of being involved in cardiac development. These genes, when mutated, are candidates for causing human CHD. Our classifier showed a cross-validation accuracy of 81% in detecting cardiac and non-cardiac genes. From our classifier we generated predictions of the cardiac development association status for all protein-coding genes in the mouse genome. We also cross-referenced our predictions with datasets of known human CHD genes, determining which are orthologues of predicted mouse cardiac genes. Our predicted cardiac genes have a high overlap with human CHD genes. Thus, our predictions could inform the prioritisation of genes when evaluating CHD patient sequence data for genetic diagnosis. Knowledge of cardiac developmental genes may speed up reaching a genetic diagnosis for patients born with CHD. Author Summary: Congenital heart disease arises during pregnancy when the heart has formed incorrectly. These malformations affect ∼1% of newborns. Yet, despite their frequency, the underlying causes are still not known in many cases. It is clear that genetic factors contribute to these defects, and increasingly DNA sequencing is used to attempt to determine if an individual has a genetic change causative of their condition. However, analysis of patient sequence data often reveals changes that are difficult to interpret due to a lack of knowledge of the function of the gene harbouring a sequence change. We aimed to facilitate the process of sequence evaluation by predicting which genes of unknown function are likely involved in heart formation. Our predictions agree with novel experimental evidence about genes needed for heart development. We found that when mutated, a high proportion of the predicted cardiac genes do indeed cause heart defects. This result suggests that our predictions may be informative for expanding our understanding of the genetic basis of congenital heart disease.